VolitionRX Ltd (VNRX) Insider Trading Activity

AMEX$0.2001+0.01 (5.18%)
Market Cap
$2.32M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
365 of 849
Rank in Industry
51 of 107

VNRX Insider Trading Activity

VNRX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$7,000
1
100
Sells
$0
0
0

Related Transactions

Reynolds Cameron JohnPresident and CEO
1
$7,000
0
$0
$7,000

About VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's …

Insider Activity of VolitionRX Ltd

Over the last 12 months, insiders at VolitionRX Ltd have bought $7,000 and sold $0 worth of VolitionRX Ltd stock.

On average, over the past 5 years, insiders at VolitionRX Ltd have bought $381,567 and sold $80,924 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Reynolds Cameron John (President and CEO) — $7,000.

The last purchase of 20,000 shares for transaction amount of $7,000 was made by Reynolds Cameron John (President and CEO) on 2025‑11‑17.

List of Insider Buy and Sell Transactions, VolitionRX Ltd

2025-11-17PurchaseReynolds Cameron JohnPresident and CEO
20,000
0.0197%
$0.35
$7,000
-60.60%
2025-10-14PurchaseReynolds Cameron JohnPresident and CEO
110,000
0.1134%
$0.51
$56,100
-64.60%
2025-10-14PurchaseSTILL TIMOTHY Idirector
48,076
0.0495%
$0.51
$24,519
-64.60%
2025-10-14PurchaseInnes Guy Archibalddirector
96,153
0.0991%
$0.51
$49,038
-64.60%
2025-09-12PurchaseReynolds Cameron JohnPresident and CEO
15,000
0.014%
$0.66
$9,885
-69.93%
2025-08-05PurchaseReynolds Cameron JohnPresident and CEO
78,125
0.0751%
$0.64
$50,000
-61.56%
2025-08-05PurchaseInnes Guy Archibalddirector
78,125
0.0751%
$0.64
$50,000
-61.56%
2025-06-12PurchaseReynolds Cameron JohnPresident and CEO
12,500
0.012%
$0.59
$7,373
-49.83%
2025-06-03PurchaseInnes Guy Archibalddirector
20,000
0.0194%
$0.54
$10,772
-41.37%
2025-05-19PurchaseReynolds Cameron JohnPresident and CEO
20,000
0.0202%
$0.44
$8,730
-16.47%
2025-05-19PurchaseMicallef Jacob VincentChief Scientific Officer
50,000
0.0496%
$0.43
$21,500
-16.47%
2025-03-26PurchaseReynolds Cameron JohnPresident and CEO
181,818
0.2024%
$0.55
$100,000
-6.80%
2025-03-26PurchaseInnes Guy Archibalddirector
181,818
0.2024%
$0.55
$100,000
-6.80%
2024-12-09PurchaseReynolds Cameron JohnPresident and CEO
139,811
0.1439%
$0.57
$80,000
-0.08%
2024-12-09PurchaseSTILL TIMOTHY Idirector
87,382
0.0899%
$0.57
$50,000
-0.08%
2024-12-09PurchaseInnes Guy Archibalddirector
174,764
0.1799%
$0.57
$100,000
-0.08%
2024-12-09PurchaseMicallef Jacob VincentChief Scientific Officer
43,691
0.045%
$0.57
$25,000
-0.08%
2024-08-20PurchaseInnes Guy Archibalddirector
150,000
0.1651%
$0.67
$100,500
-6.13%
2024-01-02SaleEight Corp Ltd10 percent owner
20,000
0.0222%
$0.90
$18,000
-32.79%
2023-12-18PurchaseButera Salvatore ThomasCEO - Volition Veterinary
10,000
0.0135%
$0.83
$8,300
-6.71%
Total: 96
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Reynolds Cameron JohnPresident and CEO
2554847
21.212%
$493,085.47162
<0.0001%
Faulkes Martin Charlesdirector
1673532
13.8948%
$322,991.6871
+2.43%
STILL TIMOTHY Idirector
1535458
12.7484%
$296,343.3920
<0.0001%
Innes Guy Archibalddirector
1062967
8.8255%
$205,152.63160
<0.0001%
Micallef Jacob VincentChief Scientific Officer
426033
3.5372%
$82,224.3790
<0.0001%
Eight Corp Ltd10 percent owner
298419
2.4777%
$57,594.8713
<0.0001%
Michel GaetanChief Operating Officer
212997
1.7684%
$41,108.4210
<0.0001%
THACHUK E DELCEO and President
100000
0.8303%
$19,300.0010
Butera Salvatore ThomasCEO - Volition Veterinary
99350
0.8249%
$19,174.55130
<0.0001%
Rootsaert Rodney GerardSecretary
78652
0.653%
$15,179.8431
+30.75%
Futcher Edwarddirector
71936
0.5973%
$13,883.6520
<0.0001%
Colman Alandirector
53937
0.4478%
$10,409.8410
Plummer NicholasGC - Volition Diagnostics
51494
0.4275%
$9,938.3410
<0.0001%
Brooke Brian GordonChief Financial Officer
50000
0.4151%
$9,650.0010
Barnes Phillipdirector
24686
0.205%
$4,764.4010
<0.0001%
THACHUK MARY ANNESecretary Treasurer
20000
0.1661%
$3,860.0010
Henshall Mickiedirector
18706
0.1553%
$3,610.2610
<0.0001%
Kway JasmineCEO - Singapore Volition
10400
0.0863%
$2,007.2010
<0.0001%
KRATOCHVIL DAVID MATTHEWChief Financial Officer
10000
0.083%
$1,930.0010
<0.0001%
Vanston David CecilCHIEF FINANCIAL OFFICER
2750
0.0228%
$530.7510
<0.0001%
Nguyen Kimdirector
2500
0.0208%
$482.5010
<0.0001%
*Gray background shows insiders who have made transactions during last year

VNRX Institutional Investors: Active Positions

Increased Positions15+35.71%778,672+2.98%
Decreased Positions18-42.86%11M-41.19%
New Positions6New458,349New
Sold Out Positions11Sold Out9MSold Out
Total Postitions39-7.14%16M-38.21%

VNRX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Lagoda Investment Management, L.P.$3,409.0010.15%12.49M+782,000+6.68%2025-09-30
Armistice Capital, Llc$2,561.007.63%9.38M+887,351+10.45%2025-09-30
Vanguard Group Inc$418.001.24%1.53M-94,683-5.83%2025-09-30
Geode Capital Management, Llc$240.000.71%878,170+113,279+14.81%2025-09-30
Blackrock, Inc.$122.000.36%445,18700%2025-09-30
Citadel Advisors Llc$90.000.27%329,520+135,775+70.08%2025-09-30
State Street Corp$73.000.22%268,638+121,000+81.96%2025-09-30
Silverberg Bernstein Capital Management Llc$63.000.19%232,082+31,300+15.59%2025-09-30
Northern Trust Corp$53.000.16%192,860+74,985+63.61%2025-09-30
Renaissance Technologies Llc$21.000.06%78,000+57,500+280.49%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.